GLP-1 and Heart Rate: Palpitations, Tachycardia, and Resting HR Evidence

Every randomized trial of a GLP-1 receptor agonist for weight loss or cardiovascular outcomes has reported the same modest signal: resting heart rate rises by roughly 2 to 4 beats per minute versus placebo, the change peaks within the first 12 weeks of titration, and it persists for as long as patients stay on therapy. The SELECT trial of semaglutide in non-diabetic adults with established cardiovascular disease (Lincoff 2023 NEJM^[1]) reported the increase alongside a 20% relative reduction in major cardiovascular events — meaning the heart-rate bump does not, in aggregate, translate into harm. Patients still feel it, though, and palpitations are one of the more common unsolicited complaints in the first months of a Wegovy or Zepbound titration. This article walks through what the data actually show, the mechanism that best fits the data, and when palpitations warrant a cardiology workup rather than reassurance.

The honest summary

• The heart-rate increase is real and consistent. Semaglutide trials (SELECT^[1], SUSTAIN-6^[2], STEP-1^[5]) show roughly +2 to +3 BPM versus placebo at steady state. Tirzepatide (SURMOUNT-1^[4] with Krumholz 2024 stratified analyses^[10]) shows +2 to +4 BPM by dose. Liraglutide (LEADER^[3], SCALE^[9]) shows +2 to +3 BPM. Retatrutide's triple-agonist Phase 2 trial (Jastreboff 2023^[6]) reports the largest signal at +5 to +7 BPM on the higher doses, likely because glucagon-receptor agonism adds an independent chronotropic push.
• The mechanism is autonomic. Baggio 2017 (Molecular Metabolism^[7]) demonstrated in knockout mice that the heart-rate effect is mediated by cardiac GLP-1 receptors plus a sympathetic-nervous-system contribution; Jons 2021^[8] mapped the liraglutide-specific positive-chronotropy pathway. The working model is direct GLP-1R signaling at the sinoatrial node combined with reduced vagal tone.
• Most palpitations are benign. Patient-reported palpitations run 5 to 15% across the major trials. Sustained resting heart rate below 100 BPM with no chest pain, shortness of breath, or syncope is almost always benign and will plateau by week 8 to 12 of titration.
• Some patients need a workup. Sustained resting HR above 100 BPM, new atrial fibrillation, palpitations with chest pain or syncope, or worsening of a known arrhythmia warrant EKG, Holter monitoring, and consideration of pausing the GLP-1.

What the trials actually report

Heart rate has been a pre-specified safety endpoint in every major GLP-1 obesity or cardiovascular outcomes trial since LEADER. The pattern is remarkably consistent across molecules and populations.

SELECT (Lincoff 2023 NEJM^[1]) randomized 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes to semaglutide 2.4 mg weekly or placebo. Mean resting heart rate rose by about 3 BPM in the semaglutide arm versus placebo at 20 weeks and persisted through 156 weeks. The same trial showed a 20% relative risk reduction in the primary composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — so the modest tachycardia did not translate into excess events.

SUSTAIN-6 (Marso 2016 NEJM^[2]) and LEADER (Marso 2016 NEJM^[3]) established the same pattern earlier in patients with type 2 diabetes: roughly +2 to +3 BPM on semaglutide and liraglutide respectively, with major cardiovascular event reductions of 26% and 13%.

STEP-1 (Wilding 2021 NEJM^[5]) randomized 1,961 adults with obesity to semaglutide 2.4 mg or placebo and reported a mean increase of about 3 BPM in the active arm. SCALE Obesity and Prediabetes(Pi-Sunyer 2015 NEJM^[9]) reported +2 to +3 BPM on liraglutide 3.0 mg.

SURMOUNT-1 (Jastreboff 2022 NEJM^[4]) on tirzepatide showed +2 to +4 BPM across the 5, 10, and 15 mg arms, with a dose-response gradient. The Krumholz 2024 stratified analysis in Heart^[10] reconfirmed the HR pattern while reporting clinically meaningful systolic blood pressure reductions of 5 to 8 mmHg — the cardiovascular trade-off looks net favorable.

Retatrutide Phase 2 (Jastreboff 2023 NEJM^[6]) is the outlier in magnitude. The triple agonist produced mean heart-rate increases of +5 to +7 BPM at the higher dose arms, plausibly because glucagon-receptor agonism contributes an independent positive-chronotropic effect on top of GLP-1R signaling. The clinical implications are still being established as the Phase 3 program reads out.

The mechanism: cardiac GLP-1 receptors and autonomic tone

The cleanest mechanistic work comes from Baggio 2017 (Molecular Metabolism^[7]), which used cardiac-specific GLP-1 receptor knockout mice to dissect the effect. The authors showed that the chronotropic response to GLP-1 receptor agonists requires both functional cardiac GLP-1 receptors (likely at the sinoatrial node) and an intact autonomic nervous system. The working model that fits the published data has two contributors:

• Direct sinoatrial GLP-1R activation raises intrinsic pacemaker firing rate.
• Central GLP-1R signaling reduces vagal tone, unmasking sympathetic input to the sinoatrial node. This is why the HR bump does not require a measurable increase in circulating catecholamines — the autonomic balance shifts even when absolute sympathetic drive looks normal.

Jons 2021 (Life Sciences^[8]) mapped the liraglutide-specific pathway in more detail and explored mitigation strategies, including the observation that beta-blocker co-therapy reliably blunts the GLP-1-induced HR increase. That finding has practical implications for patients already on metoprolol or carvedilol for heart failure or post-myocardial-infarction indications: they can usually start a GLP-1 without dose changes, and the beta-blocker dampens the chronotropic effect.

Magnitude: resting HR change by intervention

Palpitations: what patients actually feel

Palpitations — the subjective awareness of one's own heartbeat — are one of the more common unsolicited complaints in the first months of GLP-1 titration. Across the large weight-loss trials, patient-reported palpitations or increased heart rate run somewhere in the 5 to 15% range, though the elicitation methodology varies. The Wadden 2024 STEP psychiatric safety post-hoc analysis^[11]documented overlap between palpitations, anxiety, and treatment-emergent adverse events — the two often co-occur in patients who are mid-titration and adjusting to early appetite suppression, dehydration, and the autonomic shift.

The typical time course is informative: palpitations and the heart-rate increase usually appear within 2 to 4 weeks of starting a new dose step, peak around week 4 to 8, and plateau by week 12. They do not generally worsen on long-term steady-state therapy, and they do not generally resolve until the medication is stopped. Patients should be told this in advance — the symptom is far less alarming when it is expected.

When to call a cardiologist

Most palpitations on a GLP-1 are benign and can be managed with reassurance, hydration, and time. The following warrant escalation:

• Sustained resting heart rate above 100 BPM at multiple visits, especially if accompanied by symptoms.
• New atrial fibrillation documented on EKG or ambulatory monitor. The GLP-1 should generally be paused while AF is evaluated and rate or rhythm control is established.
• Palpitations with chest pain, shortness of breath, or syncope — any of these triad symptoms requires urgent evaluation regardless of medication context.
• Worsening of a known arrhythmia — patients with prior supraventricular tachycardia or well-controlled AF whose symptoms escalate after starting a GLP-1 deserve a re-evaluation.
• Heart-rate increase greater than 10 BPM from baseline — this is outside the trial-reported range and warrants ruling out competing causes (hyperthyroidism, dehydration, anemia, deconditioning).

The standard workup is straightforward: a resting 12-lead EKG, a 24 to 48 hour Holter monitor or patch-style ambulatory rhythm recorder, a thyroid-stimulating hormone level to rule out hyperthyroidism (a common confound in middle-aged adults on GLP-1s), and an echocardiogram if structural disease is suspected. For patients on the higher-risk profile (age > 65, prior cardiovascular history, planned aggressive titration), a baseline EKG before starting therapy is a reasonable precaution.

The practical protocol

1. Set expectations before starting. Tell patients to expect a 2 to 4 BPM resting heart rate increase that peaks at week 4 to 8 and persists for as long as they are on the medication. Palpitations are common and usually benign.
2. Baseline EKG for higher-risk patients. Age > 65, known cardiovascular disease, or planned maximum-dose titration are reasonable triggers for a baseline 12-lead.
3. Heart-rate check at week 4 and week 12. Pulse check at routine visits during dose titration catches the rare outlier with a sustained > 100 BPM resting rate.
4. Hydration emphasis. GLP-1-induced reduced oral intake plus any nausea/vomiting can cause dehydration, which produces reflex tachycardia independent of the direct GLP-1 effect. Encourage at least 2 liters of fluid per day during titration.
5. Beta-blocker co-therapy is compatible. Metoprolol and carvedilol blunt the GLP-1-induced heart-rate increase (Jons 2021^[8]); patients already on a beta-blocker for heart failure or post-myocardial-infarction indications can usually start a GLP-1 without dose adjustment.
6. Reassessment at 6 months. If the patient has stabilized clinically and the heart rate has plateaued within 5 BPM of baseline, continued therapy is appropriate. Persistent sustained heart rate > 100 BPM or new AF changes the calculus.

Related research and tools

• Wegovy and heart palpitations — semaglutide-specific data and the patient-facing framing
• SELECT trial cardiovascular benefits in non-diabetics — the 20% MACE reduction that frames the risk-benefit conversation
• GLP-1 in HFpEF and the SUMMIT data — tirzepatide and semaglutide in patients with heart failure with preserved ejection fraction
• GLP-1 with diuretics — furosemide, spironolactone, potassium handling, and the cardiology overlap
• Wegovy drug page — cost, dose ladder, and provider routes
• Zepbound drug page — tirzepatide for weight management

Important disclaimer. This article is educational and does not constitute medical advice. Patients with known cardiovascular disease, arrhythmia history, or unexplained palpitations should be evaluated by a clinician before starting or continuing a GLP-1 receptor agonist. The decision to pause therapy for new atrial fibrillation or sustained tachycardia should be individualized with the prescribing clinician and a cardiologist. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if new prospective trial data on GLP-1 heart-rate effects (Retatrutide Phase 3 readouts, long-term SELECT extension, or SURMOUNT cardiovascular outcomes) is published.